Chlorproguanil/dapsone

Template:Short description Template:Short description Template:Template other{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype = combo

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals= | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data= | _combo_data=ChlorproguanilDapsoneAntimalarial drugAntibiotic | _physiological_data= | _clinical_data=

| _legal_data=Withdrawn

| _other_data=

| _image_0_or_2 = | _image_LR =

| _datapage = Chlorproguanil/dapsone (data page) | _vaccine_target=_type_not_vaccine | _legal_all=Withdrawn | _ATC_prefix_supplemental= | _has_EMA_link = | CAS_number=209665-78-1 | PubChem= | ChemSpiderID= | ChEBI= | ChEMBL= | DrugBank= | KEGG= | _hasInChI_or_Key= | UNII= | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs= | _countIndexlabels= | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields= |verifiedrevid=}} Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.

References

1. REDIRECT Template:Antiinfective-drug-stub